These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 193451)

  • 1. Clinical significance of circulating C-peptide in diabetes mellitus and hypoglycemic disorders.
    Rubenstein AH; Kuzuya H; Horwitz DL
    Arch Intern Med; 1977 May; 137(5):625-32. PubMed ID: 193451
    [TBL] [Abstract][Full Text] [Related]  

  • 2. C-peptide measurement: methods and clinical utility.
    Bonser AM; Garcia-Webb P
    Crit Rev Clin Lab Sci; 1984; 19(4):297-352. PubMed ID: 6373142
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Factitious hypoglycemia. Diagnosis by measurement of serum C-peptide immunoreactivity and insulin-binding antibodies.
    Scarlett JA; Mako ME; Rubenstein AH; Blix PM; Goldman J; Horwitz DL; Tager H; Jaspan JB; Stjernholm MR; Olefsky JM
    N Engl J Med; 1977 Nov; 297(19):1029-32. PubMed ID: 198659
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Insulin biosynthesis and C-peptide. Practical applications from basic research.
    Sperling MA
    Am J Dis Child; 1980 Dec; 134(12):1119-21. PubMed ID: 7004174
    [No Abstract]   [Full Text] [Related]  

  • 5. Clinical significance of circulating proinsulin and C-peptide.
    Rubenstein AH; Steiner DF; Horwitz DL; Mako ME; Block MB; Starr JI; Kuzuya H; Melani F
    Recent Prog Horm Res; 1976; 33():435-75. PubMed ID: 198859
    [No Abstract]   [Full Text] [Related]  

  • 6. Circulating serum C-peptide. A brief review of diagnostic implications.
    Horwitz DL; Kuzuya H; Rubenstein AH
    N Engl J Med; 1976 Jul; 295(4):207-9. PubMed ID: 179006
    [No Abstract]   [Full Text] [Related]  

  • 7. C-peptide in conditions other than diabetes mellitus.
    Horwitz DL; Rubenstein AH; Mako ME; Cruz A; Blix PM
    Diabetes; 1978; 27 Suppl 1():267-71. PubMed ID: 631444
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Pancreatic B cell peptides: kinetic behaviour and concentrations of proinsulin, insulin and C-peptide in plasma and urine, problems of assay methods, clinical significance and literature review (author's transl)].
    Gerbitz KD
    J Clin Chem Clin Biochem; 1980 Jun; 18(6):313-26. PubMed ID: 7000969
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Diagnosis of islet cell adenoma].
    Bottermann P
    Med Klin; 1979 Dec; 74(51-52):1943-51. PubMed ID: 232238
    [No Abstract]   [Full Text] [Related]  

  • 10. Heterogeneity of circulating insulin and proinsulin in man.
    Horwitz DL; Rubenstein AH
    Isr J Med Sci; 1974 Oct; 10(10):1201-11. PubMed ID: 4373412
    [No Abstract]   [Full Text] [Related]  

  • 11. The use of artificial beta cell in diagnosis and treatment of insulinoma.
    Raptis S; Zoupas C; Dimitriadis G; Moulopoulos S
    Horm Metab Res Suppl; 1979; (8):169-72. PubMed ID: 231567
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Production of pro-insulin, C-peptide, and insulin in nesidioblastosis, focal islet-cell adenomatosis, and genuine insulomas. A correlated radioimmunochemical, immunohistochemical, and ultrastructural investigation with particular regard to the occurrence of argyrophil and pro-insulin immunoreactive cells.
    Kohnert KD; Fält K; Odselius R; Ziegler M; Madsen OD; Grimelius L; Falkmer S
    Diabetes Res; 1988 Aug; 8(4):151-63. PubMed ID: 2853026
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proinsulin and C-peptide: a review.
    Kitabchi AE
    Metabolism; 1977 May; 26(5):547-87. PubMed ID: 403392
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Poor beta-cell function after the clinical manifestation of type 1 diabetes in children initially positive for islet cell specific autoantibodies. The Childhood Diabetes in Finland Study Group.
    Komulainen J; Knip M; Lounamaa R; Vähäsalo P; Karjalainen J; Sabbah E; Akerblom HK
    Diabet Med; 1997 Jul; 14(7):532-7. PubMed ID: 9223390
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The occurrence of proinsulin and C-peptide in healthy humans and in diabetics].
    Beischer W
    Fortschr Med; 1982 Sep; 100(33):1508-12. PubMed ID: 7129312
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Current concepts concerning insulin resistance].
    Rossi G
    Recenti Prog Med; 1981 Sep; 71(3):264-73. PubMed ID: 7034082
    [No Abstract]   [Full Text] [Related]  

  • 17. [Proinsulin, C-peptide reactive protein (CPR)].
    Takahashi R; Oka Y
    Nihon Rinsho; 2005 Aug; 63 Suppl 8():488-92. PubMed ID: 16149558
    [No Abstract]   [Full Text] [Related]  

  • 18. Secretory function of pancreatic beta cell during insulin-induced hypoglycemia evaluated by C-peptide immunoreactivity (CPR) determination.
    Shima K; Tanaka R; Morishita S; Sawazaki N; Ichihara K; Kumahara Y; Yanaihara N
    Med J Osaka Univ; 1978 Dec; 29(3-4):221-8. PubMed ID: 379559
    [No Abstract]   [Full Text] [Related]  

  • 19. C-peptide, Na+,K(+)-ATPase, and diabetes.
    Vague P; Coste TC; Jannot MF; Raccah D; Tsimaratos M
    Exp Diabesity Res; 2004; 5(1):37-50. PubMed ID: 15198370
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [C-peptide measurement in the classification of diabetes mellitus and in the assessment of requirements for insulin treatment].
    Gjessing HJ
    Ugeskr Laeger; 1990 Feb; 152(9):588-93. PubMed ID: 2408222
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.